

CLAIMS

1. Use of a composition for symptomatic relief, when needed, comprising, in admixture

5 (a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and

(b) a second active ingredient which is budesonide;

for the manufacture of a medicament for use in the prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma.

10

2. Use according to claim 1, wherein the molar ratio of (a) to (b) calculated as formoterol to budesonide is from 1:1 to 1:100, preferably from 1:1 to 1:70.

15

3. Use according to claim 1 or 2, wherein the first active ingredient is formoterol fumarate dihydrate.

4. Use according to any previous claim, wherein the first active ingredient is the R,R enantiomer of formoterol.

20

5. Use according to any previous claim, wherein a unit dose of formoterol lies in the range of from 1 μ g to 48 μ g, preferably between 3 μ g to 12 μ g, calculated as formoterol fumarate dihydrate.

25

6. Use according to any previous claim, wherein the daily dose of formoterol, including maintenance therapy, lies in the range of from 1 μ g to 100 μ g, preferably from 2 μ g to 60 μ g, calculated as formoterol fumarate dihydrate.

7. Use according to any previous claim, wherein the second active ingredient is the 22R epimer of budesonide.

30

09367950-081899

8. Use according to any previous claim, wherein a unit dose of budesonide lies in the range of from 20 μg to 1600 μg , preferably between 50 μg to 400 μg .

9. Use according to any previous claim, wherein the daily dose of budesonide, including maintenance therapy, lies in the range of from 20 μg to 4800 μg , preferably from 30 μg to 3200 μg .

10. Use according to any previous claim, wherein the particle size of the active ingredients (a) and (b) is less than 10 μm .

11. Use according to any previous claim, wherein the composition additionally comprises one or more pharmaceutically acceptable additives, diluents or carriers.

12. Use according to claim 11, wherein the pharmaceutically acceptable additive, diluent or carrier is lactose monohydrate.

13. A method of prevention or treatment of an acute condition of asthma and/or intermittent asthma and/or episodes in chronic asthma, when needed, which comprises administering, by inhalation, to a patient an effective amount of a composition comprising, in admixture:

- (a) a first active ingredient which is formoterol, a pharmaceutically acceptable salt or solvate thereof or a solvate of such a salt; and
- (b) a second active ingredient which is budesonide.

14. The method according to claim 13, wherein the molar ratio of (a) to (b) calculated as formoterol to budesonide is from 1:1 to 1:100, preferably from 1:1 to 1:70.

15. The method according to claim 13 ~~or 14~~, wherein the first active ingredient is formoterol fumarate dihydrate.

09367950 081869
SUB
BI

16. The method according to ~~any of claims 13 to 15~~, previous claim, wherein the first active ingredient is the R,R enantiomer of formoterol.

17. The method according to ~~any of claims 13 to 16~~, wherein a unit dose of formoterol lies in the range of from 1 μg to 48 μg , preferably between 3 μg to 12 μg , calculated as formoterol fumarate dihydrate.

18. The method according to ~~any of claims 13 to 17~~, wherein the daily dose of formoterol, including maintenance therapy, lies in the range of from 1 μg to 100 μg , preferably from 2 μg to 60 μg , calculated as formoterol fumarate dihydrate.

19. The method according to ~~any of claims 13 to 18~~, wherein the second active ingredient is the 22R epimer of budesonide.

20. The method according to ~~any of claims 13 to 19~~, wherein a unit dose of budesonide lies in the range of from 20 μg to 1600 μg , preferably between 50 μg to 400 μg .

21. The method according to ~~any of claims 13 to 20~~, wherein the daily dose of budesonide, including maintenance therapy, lies in the range of from 20 μg to 4800 μg , preferably from 30 μg to 3200 μg .

22. The method according to ~~any of claims 13 to 21~~, wherein the particle size of the active ingredients (a) and (b) is less than 10 μm .

23. The method according to ~~any of claims 13 to 22~~, wherein the composition additionally comprises one or more pharmaceutically acceptable additives, diluents or carriers.

24. The method according to claim 23, wherein the pharmaceutically acceptable additive, diluent or carrier is lactose monohydrate.

claim 13

claim 13

claim 13

claim 13

claim 13

claim 13

claim 13

claim 13

093679500081899

Sub
B2Sub
B3Add
B4add
B27